Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.
Boston Pharmaceuticals announced positive Phase 2a results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 analog for the treatment of non-alcoholic steatohepatitis.
Desde tiempos inmemoriales, los seres humanos han buscado la manera de vencer a la muerte y prolongar indefinidamente nuestra existencia. A medida que la ciencia avanza a pasos agigantados, se plantea la pregunta: ¿podremos algún día alcanzar la inmortalidad? Veamos los avances …
El sueño de la inmortalidad: ¿Es posible desafiar a la muerte? Read More »
En el vasto y misterioso mundo submarino, las ballenas han desarrollado una forma de comunicación única y compleja. Estos majestuosos mamíferos marinos han cautivado a científicos y amantes de la naturaleza durante décadas con su capacidad para comunicarse a largas …
Biovica signed a commercial partnership agreement for the use of DiviTum TKa in Italy.
Year-end Report 2022/2023 – Commercial Agreements Signed in the US and Europe! Read More »
Jadeite Medicines Inc., a clinical stage biopharmaceutical company headquartered in Tokyo, Japan has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of Health, Labour and Welfare of Japan.
Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, announced the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA.
CymaBay Therapeutics, Inc. announced new findings from a post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis demonstrating baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31.
UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study with oral orismilast in adult patients with HS.
Desde que los primeros fósiles de dinosaurios fueron descubiertos, hemos estado fascinados por estas criaturas prehistóricas que dominaron la Tierra durante millones de años. Entre la variedad de especies que existieron, uno de los temas más cautivadores es el de los dino …
El dinosaurio más grande de todos los tiempos: Una mirada a los gigantes prehistóricos Read More »
